FRAMINGHAM, Mass., May 27, 2021 /PRNewswire/ — Clinical Enterprise, Inc., a Eurofins Scientific company, today announced it has been awarded a U.S. Government agreement to expand national COVID-19 testing. The agreement with the U.S. Department of Health and Human Services, in coordination with the U.S. Department of Defense (DOD), will expand testing opportunities in K-8 schools, underserved populations and congregate settings such as homeless shelters. Eurofins has been awarded the agreement to test up to 24.6 million people in the Northeast and South regions.
The goals of the government-funded program are to help identify and minimize asymptomatic transmission, curtail broader community transmission, prevent outbreaks in institutional and community settings, and protect vulnerable individuals and populations.
Eurofins U.S. Clinical Diagnostics companies, which operate a network of 20 CLIA-certified labs, have been at the forefront of COVID-19 testing. Eurofins launched its first RT-PCR assay for SARS-CoV-2 in the U.S. on March 13, 2020. The FDA-emergency use authorized assay, developed by Eurofins Viracor, Inc., is ranked one of the most sensitive on the market, according to the FDA’s SARS-CoV-2 Reference Panel.1
Eurofins’ U.S. COVID-19 program is centered on pooled surveillance PCR tests, where any positive pools reflex immediately to individual diagnostic testing. This method helps identify positive individuals in a timely manner without the need to re-test. Eurofins’ high ratio pooling (24:1) combines low cost testing with a highly sensitive test, which is ideal for early detection in community and school settings.
Eurofins will partner with Affinity Empowering, Inc., a leading provider of the most sophisticated and secure occupational, behavioral, and direct-to-consumer health services, to scale school and community outreach across both regions. Affinity has developed a fully integrated, HIPAA-compliant technology platform, Assure™, which will be used as the end-to-end platform to provide up-to-the-minute scheduling, test results, and reports, as well as rapid issue remediation safely and securely.
Eurofins was one of 187 vendors vying for the national COVID-19 testing agreement, which was awarded on May 25th. Outreach to schools and community- based organizations will begin immediately.
ABOUT EUROFINS – THE GLOBAL LEADER IN BIO-ANALYSIS
Eurofins is Testing for Life. The Eurofins companies are global leaders in food, environment, and pharmaceutical product testing. They are also market leaders in testing and laboratory services for genomics, discovery pharmacology, forensics, and advanced material sciences, and have a rapidly developing presence in highly specialised and molecular clinical diagnostic testing. With over 50,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins companies offer a portfolio of over 200,000 analytical methods.
Eurofins Shares are listed on Euronext Paris Stock Exchange.
1 As of May 2021, Eurofins Viracor’s SARS-CoV-2 assay offers the best sensitivity of the 117 laboratories that have submitted results to FDA’s SARS-CoV-2 Reference Panel, with a limit of detection (LoD) of 180 NAAT Detectable Units/mL1. Source:https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-reference-panel-comparative-data#results
SOURCE Eurofins U.S. Clinical Diagnostics